Bausch Health’s four-year-old plan to spin off eye-care subsidiary Bausch + Lomb is caught in a standoff between the pharmaceutical company’s top shareholders including Carl Icahn and Paulson & Co. and debtholders favoring a bankruptcy filing to fix its balance sheet, according to people familiar with the situation.
